about
Evaluation of Factors Influencing Antibody Reduction for Development of Antibody Drug ConjugatesGrowth-Inhibitory and Apoptosis-Inducing Effects of Punica granatum L. var. spinosa (Apple Punice) on Fibrosarcoma Cell Lines.Biomedical applications of yeast- a patent view, part one: yeasts as workhorses for the production of therapeutics and vaccines.An H1-H3 chimeric influenza virosome confers complete protection against lethal challenge with PR8 (H1N1) and X47 (H3N2) viruses in mice.Development of an effective delivery system for intranasal immunization against Mycobacterium tuberculosis ESAT-6 antigen.Oligoasthenoteratozoospermic (OAT) men display altered phospholipase C ζ (PLCζ) localization and a lower percentage of sperm cells expressing PLCζ and post-acrosomal sheath WW domain-binding protein (PAWP).Development of high-affinity monoclonal antibody using CD44 overexpressed cells as a candidate for targeted immunotherapy and diagnosis of acute myeloid leukemia.Regulatory T and T helper 17 cells: Their roles in preeclampsia.A developed antibody-drug conjugate rituximab-vcMMAE shows a potent cytotoxic activity against CD20-positive cell line.Development of a novel explant culture method for the isolation of mesenchymal stem cells from human breast tumor.Development of a new anti-CD123 monoclonal antibody to target the human CD123 antigen as an acute myeloid leukemia cancer stem cell biomarkerHow hypoxia regulate exosomes in ischemic diseases and cancer microenvironment?The role of microRNAs regulating the expression of matrix metalloproteinases (MMPs) in breast cancer development, progression, and metastasisTrastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancerNickel-Doped Cerium Oxide Nanoparticles: Green Synthesis Using Stevia and Protective Effect against Harmful Ultraviolet RaysEmerging roles of exosomal miRNAs in breast cancer drug resistanceProtective effects of pharmacological agents against aminoglycoside-induced nephrotoxicity: A systematic reviewThe role of Human leukocyte antigen class I on patient survival in Gastrointestinal cancers: a systematic review and meta- analysisPotential drugs used in the antibody-drug conjugate (ADC) architecture for cancer therapyAntibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successesKey regulatory microRNAs and their interplay with mechanosensing and mechanotransduction signaling pathways in breast cancer progressionBiomedical applications of yeasts - a patent view, part two: era of humanized yeasts and expanded applications
P50
Q33766408-D54A9DC1-61A6-4A4B-8052-E0C2EB02526DQ35033255-A588AAD0-E3A9-4A57-9D55-5BB732E9D71DQ38671575-52FD2EAE-999D-4A8B-A430-55AFC93B9DC8Q38971243-269AEC5A-72F3-402B-8EE1-1934DE19EC93Q39961868-559065DF-F4D1-42C2-910C-D6869D485772Q47735879-BAB63079-2E76-4A7C-8565-7899D5302352Q51107775-077D96E9-B59C-4CBD-A256-6AC1F58F04CEQ52583932-D634B74E-73D7-43E9-A629-379DE8C1FF90Q53703327-4D2B7AEA-3CC4-4B2B-AFA1-75A1A3A30B36Q54379718-42A67814-DB8B-4008-AEB0-C3228DCDF622Q89418834-32A8ABAE-5518-4360-994E-CE46CE606FEDQ90513676-CE180D45-B582-49BA-96A3-09552E5DE711Q90630324-8C496082-A1F7-469E-B640-0CF04C3FDA26Q91673414-0FF7FD2E-F847-487A-9E88-AF2912034619Q91808904-D9958A80-22CB-4644-A5F3-A8AD51CE416AQ92019699-F8617B27-F218-4908-81E0-3F4BEA31F834Q92497350-18FDD600-CB71-4ACD-BE66-48B56952E0CCQ92783664-4CF1B8E8-9D64-40CF-B51E-DBA429C58DB2Q92867774-47BCDF59-FBE3-41BF-B699-BAFAAB7212A3Q93384466-046EA342-5A71-4111-9D1D-E92985A00F9BQ95264410-7A033510-28BE-4A78-9AF6-3F64E078EA3AQ96307388-28ED8044-C8EC-4CC6-8BF1-9C2C4CC01EF4
P50
description
researcher ORCID ID = 0000-0002-5260-2527
@en
name
Meghdad Abdollahpour-Alitappeh
@ast
Meghdad Abdollahpour-Alitappeh
@en
Meghdad Abdollahpour-Alitappeh
@es
Meghdad Abdollahpour-Alitappeh
@nl
type
label
Meghdad Abdollahpour-Alitappeh
@ast
Meghdad Abdollahpour-Alitappeh
@en
Meghdad Abdollahpour-Alitappeh
@es
Meghdad Abdollahpour-Alitappeh
@nl
prefLabel
Meghdad Abdollahpour-Alitappeh
@ast
Meghdad Abdollahpour-Alitappeh
@en
Meghdad Abdollahpour-Alitappeh
@es
Meghdad Abdollahpour-Alitappeh
@nl
P1153
56433588400
P31
P496
0000-0002-5260-2527